Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 5, Issue 214, Pages 214ra168-214ra168
Publisher
American Association for the Advancement of Science (AAAS)
Online
2013-12-05
DOI
10.1126/scitranslmed.3007355
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis
- (2013) Lluís Ballell et al. ChemMedChem
- Time-Dependent Inhibition and Induction of Human Cytochrome P4503A4/5 by an Oral IAP Antagonist, LCL161, In Vitro and In Vivo in Healthy Subjects
- (2013) Shyeilla Dhuria et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Preliminary Structure–Activity Relationships and Biological Evaluation of Novel Antitubercular Indolecarboxamide Derivatives Against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains
- (2013) Oluseye K. Onajole et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, Synthesis, and Biological Evaluation of Indole-2-carboxamides: A Promising Class of Antituberculosis Agents
- (2013) Ravinder Reddy Kondreddi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
- (2013) Kevin Pethe et al. NATURE MEDICINE
- Advances in the development of new tuberculosis drugs and treatment regimens
- (2013) Alimuddin Zumla et al. NATURE REVIEWS DRUG DISCOVERY
- Tetrahydropyrazolo[1,5-a]Pyrimidine-3-Carboxamide and N-Benzyl-6′,7′-Dihydrospiro[Piperidine-4,4′-Thieno[3,2-c]Pyran] Analogues with Bactericidal Efficacy against Mycobacterium tuberculosis Targeting MmpL3
- (2013) Modesto J. Remuiñán et al. PLoS One
- Approval of Novel TB Drug Celebrated--With Restraint
- (2013) J. Cohen SCIENCE
- Identification of Novel Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening
- (2012) Sarah A. Stanley et al. ACS Chemical Biology
- SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis
- (2012) Kapil Tahlan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- MmpL Genes Are Associated with Mycolic Acid Metabolism in Mycobacteria and Corynebacteria
- (2012) Cristian Varela et al. CHEMISTRY & BIOLOGY
- Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action
- (2012) Katherine A Sacksteder et al. Future Microbiology
- New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future
- (2012) Christian Lienhardt et al. JOURNAL OF INFECTIOUS DISEASES
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
- (2012) Andreas H Diacon et al. LANCET
- Transporter targeted in tuberculosis
- (2012) Stewart T Cole Nature Chemical Biology
- Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane
- (2012) Anna E Grzegorzewicz et al. Nature Chemical Biology
- Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
- (2012) Joanne Bowes et al. NATURE REVIEWS DRUG DISCOVERY
- MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212
- (2011) Valentina La Rosa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Assessment of Cytochrome P450 Enzyme Inhibition and Inactivation in Drug Discovery and Development
- (2011) David O. Nettleton et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Selection of oral bioavailability enhancing formulations during drug discovery
- (2011) Weijia Zheng et al. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
- Challenges and opportunities in developing novel drugs for TB
- (2011) Takushi Kaneko et al. Future Medicinal Chemistry
- Discovery and characterization of a unique mycobacterial heme acquisition system
- (2011) M. V. Tullius et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cardiac Ion Channel Safety Profiling on the IonWorks Quattro Automated Patch Clamp System
- (2010) Xueying Cao et al. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
- Optimisation of Bioluminescent Reporters for Use with Mycobacteria
- (2010) Nuria Andreu et al. PLoS One
- A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy
- (2010) Kevin Pethe et al. Nature Communications
- Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches
- (2009) Natilie A. Hosea et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
- (2009) V. Makarov et al. SCIENCE
- Artificial Membrane Assays to Assess Permeability
- (2008) Bernard Faller CURRENT DRUG METABOLISM
- Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug
- (2004) Lee Jia et al. BRITISH JOURNAL OF PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started